2024 Dermatology Conferences Recap: Part 1

January

Winter Clinical Hawaii

• Aloha to New Delgocitinib and Tralokinumab Data
• DermTech’s 2-GEP Assay Succeeds at Guiding Biopsy Decision-Making for Ambiguous Skin Lesions of All Skin Phototypes
• Majority of Patients Treated With Roflumilast Cream 0.15% for AD Demonstrate Improvement in EASI Scores at 4 Weeks
• Dialing Into the Therapeutic Hotline with Gary Goldenberg, MD

Maui Derm Hawaii

• Guselkumab Significantly Clears Scalp Psoriasis in Patients With Skin of Color in Phase 3b VISIBLE
• Maral Kibarian Skelsey, MD, Shares Insights Into DermTech’s 2-GEP Assay Success
• Trifarotene Yields Significant Improvements in Post-Inflammatory Hyperpigmentation
• Study Points Toward Stark Disparity of Academic Papers Referencing Sunscreen in Patients With Skin of Color

IMCAS World Congress

• POLL: Are You Attending IMCAS World Congress 2024?
• Glynis Ablon, MD, Previews IMCAS World Congress 2024

February

South Beach Symposium

• IGA, EASI, and Itch Endpoints Met in First In Human Phase 2 Trial of Zabalafin for Atopic Dermatitis

Winter Clinical Miami

• Trust 2 Study Validates DermTech’s 2-GEP 99% Negative Predictive Value

Masterclasses in Dermatology

• Exploring the Role of Alternative Medicine in Dermatology
• Advancements in Molecular Profiling: Differentiating Skin Diseases Through Non-Invasive Techniques
• Cutaneous Lupus Considerations with Joseph Merola, MD, MMSc
• Managing Dermatologic Surgery Challenges

March

American Academy of Dermatology

• Late-Breaking Data: Upadacitinib for Vitiligo Achieves Skin Repigmentation Through Week 52
• Late-Breaking Data: Lutikizumab Shows Positive Results in Difficult-to-Treat HS After Failed TNF Therapy
• Lawrence Eichenfield, MD: Outlining Late-Breaking INTEGUMENT-PED Data for Roflumilast in Pediatric Patients
• Award-Winning Research on Hair Loss Consensus Highlighted at Annual Meeting

Diversity in Dermatology

• Mona Shahriari, MD, FAAD: 'The Days of Paternalistic Medicine Are Gone'
• Shanna Miranti, MPAS, PA-C, Shares Highlights From Diversity in Dermatology Meeting
• Brittany Scurto, PA-C: How to Discuss an Integrative Medicine Approach With Patients
• Tracee Blackburn, PA-C: Gut Health for Healthy Skin

May

American College of Mohs Surgery Meeting

• SLIDESHOW: Showcasing Melanoma Research at the 56th Annual ACMS Meeting
• Mohs Surgical Training Around the World: Need for Standardized Database

Science Enhanced Anatomy Safety Outcomes Network (SEASON) Aesthetic

• Social Media’s Influence on Consumers, TrenibotulinumtoxinE, and More From the SEASON Aesthetic Conference

Fall Clinical Dermatology Conference for PAs & NPs

• Unraveling the Advancements in Seborrheic Dermatitis Treatment
• Generalized Pustular Psoriasis: Recent Advancements, Resources, and Cytokine Considerations
• 2024 Pediatric Pearls With Karan Lal, DO
• Combining Systemic Therapies in Psoriasis and Atopic Dermatitis

New Wave Dermatology

• Shanna Miranti, MPAS, PA-C: Pearls and Looking Ahead to New Wave Dermatology 2024

June

Society of Dermatology Physician Associates Summer Conference

• A Conversation With Amber Blair, MMS, PA-C, at the SDPA Conference
• Opening Doors of Communication: Social Media Trends and Challenges
• Career Insights: Advocating and Negotiating for PAs
• SDPA Membership Ratifies Name Change and Embraces “Associate”

Society for Investigative Dermatology

• Alice Gottlieb, MD, PhD: Preventing Pain and Disability in Psoriatic Disease

Revolutionizing Alopecia, Vitiligo, and Eczema

• Don’t Forget to Address Autoimmune Comorbidities of Atopic Dermatitis
• Safety vs Efficacy: What AD Treatments Can Be Used in Pediatric Patients?
• Late-Breaker: Roflumilast Cream 0.15% Demonstrates Continued Improvement in AD Symptoms Through 56 Weeks
• Late-Breaker: Positive 52-week Data for Rademikibart in Patients with AD

Review our full conference coverage from the year here.